Fosamprenavir
This prodrug is converted in the body to amprenavir, an HIV protease inhibitor that blocks an enzyme the virus needs to make functional copies of itself. It is used as part of combination antiretroviral therapy to treat HIV infection.
Peso Molecular
585,6000 g/mol
LogP
1,80
TPSA
186,00 Ų
Regra dos 5 de Lipinski
Reprovado
Áreas Terapêuticas
Mecanismo de Ação
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1
InChI
InChI=1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1
Molecular Formula
C25H36N3O9PS
HBD / HBA
4 / 11
Ligações Rotacionáveis
14
Átomos Pesados
39
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
This prodrug is converted in the body to amprenavir, an HIV protease inhibitor that blocks an enzyme the virus needs to make functional copies of itself. It is used as part of combination antiretroviral therapy to treat HIV infection.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Fosamprenavir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1664. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 131536. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="fosamprenavir"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/fosamprenavir/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/fosamprenavir/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/fosamprenavir/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="fosamprenavir"></drugfyi-drug>